


UNIVERSITY COLLEGE LONDON MEDICAL SCHOOL  
DIVISION OF MEDICINE



Mark Pohl,  
Pharmaceutical Patent Attorney  
Pharmaceutical Patent Attorneys, LLC,  
55 Madison Avenue, 4th Floor  
Morristown, NJ 07960-7397  
USA

31 July 2013

Dear Mr Pohl,

Thank you for asking me to comment on the possible effect on my prescribing of a 'warning letter' from the US Food and Drug Administration.

I am a full Professor of Medicine and practising internist here at University College London and its associated hospitals.

It would be my view that I would only prescribe a drug that had an FDA warning in place under very special circumstances. Here, we would almost certainly need approval from the local hospital 'Use of Medicines' committee, which oversees unusual and possibly risky deployments of medicines. The position would have to be discussed with the patient.

A handwritten signature in black ink, which appears to read 'Gordon Stewart', is located below the main text of the letter.

GW Stewart MBChB  
Professor of Experimental Medicine  
Honorary Consultant Physician

Prof Gordon Stewart  
Sub-Dean, MBPhDs  
Division of Medicine  
University College London Gower Street London WC1E 6BT  
Tel: +44 (0)20 7679 6193 Mobile 07776 188438 Fax: +44 (0)20 7679 0967  
g.stewart@ucl.ac.uk